212 related articles for article (PubMed ID: 22138096)
1. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
Perez EA; Dueck AC; McCullough AE; Reinholz MM; Tenner KS; Davidson NE; Gralow J; Harris LN; Kutteh LA; Hillman DW; Jenkins RB; Chen B
J Natl Cancer Inst; 2012 Jan; 104(2):159-62. PubMed ID: 22138096
[TBL] [Abstract][Full Text] [Related]
2. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
Wolff AC; Hammond ME; Hayes DF
J Natl Cancer Inst; 2012 Jun; 104(12):957-8. PubMed ID: 22581974
[No Abstract] [Full Text] [Related]
3. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
Crozier JA; Moreno-Aspitia A; Ballman KV; Dueck AC; Pockaj BA; Perez EA
Cancer; 2013 Jul; 119(13):2447-54. PubMed ID: 23585192
[TBL] [Abstract][Full Text] [Related]
4. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
5. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
Perez EA; Reinholz MM; Hillman DW; Tenner KS; Schroeder MJ; Davidson NE; Martino S; Sledge GW; Harris LN; Gralow JR; Dueck AC; Ketterling RP; Ingle JN; Lingle WL; Kaufman PA; Visscher DW; Jenkins RB
J Clin Oncol; 2010 Oct; 28(28):4307-15. PubMed ID: 20697084
[TBL] [Abstract][Full Text] [Related]
6. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
7. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
Perez EA; Jenkins RB; Dueck AC; Wiktor AE; Bedroske PP; Anderson SK; Ketterling RP; Sukov WR; Kanehira K; Chen B; Geiger XJ; Andorfer CA; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow JR; Harris LN; Ingle JN; Lingle WL; Reinholz MM
J Clin Oncol; 2011 Feb; 29(6):651-9. PubMed ID: 21245420
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Perez EA; Romond EH; Suman VJ; Jeong JH; Sledge G; Geyer CE; Martino S; Rastogi P; Gralow J; Swain SM; Winer EP; Colon-Otero G; Davidson NE; Mamounas E; Zujewski JA; Wolmark N
J Clin Oncol; 2014 Nov; 32(33):3744-52. PubMed ID: 25332249
[TBL] [Abstract][Full Text] [Related]
9. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
Perez EA; Dueck AC; McCullough AE; Chen B; Geiger XJ; Jenkins RB; Lingle WL; Davidson NE; Martino S; Kaufman PA; Kutteh LA; Sledge GW; Harris LN; Gralow JR; Reinholz MM
J Clin Oncol; 2013 Jun; 31(17):2115-22. PubMed ID: 23650412
[TBL] [Abstract][Full Text] [Related]
10. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
[TBL] [Abstract][Full Text] [Related]
11. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.
Murthy RK; Varma A; Mishra P; Hess KR; Young E; Murray JL; Koenig KH; Moulder SL; Melhem-Bertrandt A; Giordano SH; Booser D; Valero V; Hortobagyi GN; Esteva FJ
Cancer; 2014 Jul; 120(13):1932-8. PubMed ID: 24677057
[TBL] [Abstract][Full Text] [Related]
12. Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.
Stoss OC; Scheel A; Nagelmeier I; Schildhaus HU; Henkel T; Viale G; Jasani B; Untch M; Rüschoff J
Mod Pathol; 2015 Dec; 28(12):1528-34. PubMed ID: 26403781
[TBL] [Abstract][Full Text] [Related]
13. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
Shah MV; Wiktor AE; Meyer RG; Tenner KS; Ballman KV; Green SJ; Sukov WR; Ketterling RP; Perez EA; Jenkins RB
J Clin Oncol; 2016 Oct; 34(29):3502-3510. PubMed ID: 27458302
[TBL] [Abstract][Full Text] [Related]
14. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
15. Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory.
Gulbahce HE
Am J Clin Pathol; 2017 Oct; 148(4):308-313. PubMed ID: 28967951
[TBL] [Abstract][Full Text] [Related]
16. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
17. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
Press MF; Sauter G; Buyse M; Fourmanoir H; Quinaux E; Tsao-Wei DD; Eiermann W; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Mackey JR; Bee V; Ma Y; Villalobos I; Campeau A; Mirlacher M; Lindsay MA; Slamon DJ
J Clin Oncol; 2016 Oct; 34(29):3518-3528. PubMed ID: 27573653
[TBL] [Abstract][Full Text] [Related]
18. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
Perez EA; Thompson EA; Ballman KV; Anderson SK; Asmann YW; Kalari KR; Eckel-Passow JE; Dueck AC; Tenner KS; Jen J; Fan JB; Geiger XJ; McCullough AE; Chen B; Jenkins RB; Sledge GW; Winer EP; Gralow JR; Reinholz MM
J Clin Oncol; 2015 Mar; 33(7):701-8. PubMed ID: 25605861
[TBL] [Abstract][Full Text] [Related]
19. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
[TBL] [Abstract][Full Text] [Related]
20. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
